ADVA
14.7.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s partnering with OTN Systems to address key connectivity challenges for industrial applications. The companies are teaming up to offer joint end-to-end networking solutions built with best-in-class technology and specifically designed for the industry sector. Now customers in transportation, oil and gas, mining and electrical power utilities can smoothly transition from their legacy SONET/SDH infrastructure and realize the benefits of packet transport. Featuring OTN Systems’ XTran MPLS-TP layer combined with ADVA FSP 3000 OLS technology, the tailor-made solutions are ruggedized for the harshest environments. They also provide stringent synchronization and comprehensive in-service monitoring, ensuring the levels of availability needed for the most advanced industrial demands.
”By joining forces with ADVA, we’re giving customers the full benefits of our combined innovation and expertise. Our companies share a goal of helping all industries on their digital transformation journeys. By delivering integrated end-to-end networks that precisely meet sector-specific requirements, we’re empowering our customers to take that next step,” said Jurgen Michielsen, CTO, OTN Systems. “From transportation to electric utilities, today’s industrial networks operators are looking for a seamless way to evolve their old SONET/SDH infrastructure to high-capacity packet-based network technology. The joint solution allows customers to make the jump to the next generation of telecom architecture simple, risk-free and extremely cost-effective.”
To keep pace with the demands of new applications, industrial networks must deliver greater bandwidth and improved quality of service. They need technology that supports an easy transition from increasingly obsolete SONET/SDH networks to packet-optical transport architectures. That’s precisely what ADVA and OTN Systems’ joint solutions provide. They enable operational infrastructure to cater for ever-increasing amounts of data traffic and support industrial automation. The combined solutions include the ADVA FSP 3000 OLS, which efficiently transports wavelengths over long distances using multiplexing, amplification, dispersion compensation, power leveling and wavelength routing. This is combined with OTN Systems’ XTran multi-service MPLS-TP platform designed for industrial applications. Growing security threats are also addressed with the protection of ADVA FSP 3000 ConnectGuard™ Optical encryption as well as strict synchronization needs with ADVA’s Oscilloquartz portfolio.
“We’re teaming up with OTN Systems to deliver industrial connectivity with a unique set of benefits. Together we can provide the most reliable and secure end-to-end networking solutions on the market – solutions that are fully optimized for next-generation industrial applications and specifically designed to withstand the most extreme environments,” commented Christoph Glingener, CTO, ADVA. “Our FSP 3000 enables industrial networks to minimize both cost per bit and operational efforts. Our joint customers can also further enhance performance and reduce operating costs with our ADVA ALM fiber monitoring solution. This gives industrial network operators full control with real-time insight into the fiber plant. What’s more, our Oscilloquartz technology range ensures the precise synchronization needed for ultra-low latency use cases.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About OTN Systems
OTN systems is a leading supplier of mission-critical telecommunication solutions to industrial customers for more than 30 years. The company has developed a unique next generation platform tailored for industrial applications. XTran is a flexible, state-of-the-art product allowing customers to go full packet. Its underlying MPLS-TP technology avoids the complexity of generic telecom solutions developed for service providers. XTran secures reliable operations in a harsh environments, while its management system (TXCare) supports an intuitive and simple handling. Since its market introduction back in 2014, more than 100 customers worldwide have deployed XTran. For more information on our product and services offering, please visit us at www.otnsystems.com
, allowing you to fully appreciate how “we make MPLS for Operational Telecom easy.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005053/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom